Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cityview: PET Imaging of CIT-013 in Rheumatoid Arthritis
NCT07147959Phase 2Completed
- Sponsor
- Citryll
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CIT013 in rheumatoid arthritis (RA), sponsored by Citryll. Primary endpoint: Distribution of radiolabeled CIT-013 at 24 hours. Started Jan 2026; status: completed.
02
Drugs
CIT013
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07147959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147959.